Assembly Biosciences, Inc. (NASDAQ:ASMB) CEO Jason A. Okazaki Sells 1,569 Shares

Assembly Biosciences, Inc. (NASDAQ:ASMB) CEO Jason A. Okazaki sold 1,569 shares of the business’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $12.71, for a total value of $19,941.99. Following the transaction, the chief executive officer now directly owns 16,423 shares of the company’s stock, valued at $208,736.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Assembly Biosciences Stock Up 6.4 %

NASDAQ ASMB opened at $13.27 on Thursday. Assembly Biosciences, Inc. has a 12 month low of $7.69 and a 12 month high of $20.04. The firm’s fifty day moving average price is $13.17 and its 200 day moving average price is $11.15.

Hedge Funds Weigh In On Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Acuitas Investments LLC purchased a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 265,585 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Acuitas Investments LLC owned 0.40% of Assembly Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 19.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. StockNews.com upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, April 5th. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, April 1st.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.